Background. There is a decrease in antibody levels after hematopoietic stem cell transplant (HSCT), and such patients may be at increased risk of acquiring vaccine-preventable infection. A simple and validated revaccination schedule is required. The aim of this study was to evaluate the immunogenicity of a revaccination schedule for pediatric HSCT recipients.
humoral and cell-mediated immunity is seen after transplantation. The degree of immunodeficiency is determined by many factors, particularly by the type of transplant and the presence of graft-versus-host disease (GvHD). Immunodeficiency is generally less profound after autologous HSCT than after allogeneic HSCT [1] , and among allogeneic HSCT transplant recipients, it is less profound in patients without GvHD [2, 3] .
Immune reconstitution after HSCT occurs in a welldefined manner over a period of months to years [4] . Prolonged immunodeficiency arises from a deficiency of the more specialized functions of the adaptive immune system-in particular, of helper T lymphocytes [2, [4] [5] [6] . B lymphocyte function generally recovers earlier (after 6-12 months) [3] [4] [5] 7] than T lymphocyte function (after 1-2 years) [4] [5] [6] . Immune response to antigens is low and the risk of infectious complications is high during immune reconstitution.
An increasing number of children survive HSCT. Therefore, it is important to study the long-term effects of HSCT, such as the persistence of immunity to vaccine-preventable diseases. Studies have demonstrated low levels of immunity against measles, mumps, and rubella (MMR) [8, 9] ; poliovirus [10, 11] ; tetanus [12, 13] ; and Streptococcus pneumoniae [14] .
The immune response of HSCT recipients to revaccination against measles [8, 9] , poliovirus [10, 11] , tetanus toxoid [12, 13] , and Haemophilus influenzae type b (Hib) [15] is variable. Poor responses to polysaccharide vaccines have limited their use in HSCT recipients [14, 16] , and there are limited data on the immunogenicity of the new polysaccharide-protein conjugate vaccines.
A survey of revaccination schedules by the European Group for Blood and Marrow Transplant revealed wide variations in practice [17] . There are few controlled studies on this subject on which to base recommendations, and guidelines are therefore often based on expert opinion. This was the basis of the current British guidelines, which were published in 2002 [18] . Updated European Group for Blood and Marrow Transplant guidelines were published in 2005 [19] . Compared with the British guidelines, these do not differentiate transplantation types and suggest earlier vaccination (e.g., 6 months after HSCT for most vaccines, but 24 months after HSCT for MMR) [19] .
The primary objectives of this study were to evaluate the persistence of vaccine-specific antibody after HSCT in children and the immunogenicity of measles, tetanus, inactivated polio, Hib conjugate, and meningococcus C conjugate (MCC) vaccines. An additional objective was to compare the immunogenicity of the heptavalent pneumococcal conjugate (PCV7) and 23-valent pneumococcal polysaccharide (Pn-PS23) vaccines.
PATIENTS AND METHODS
Patient population. The study was conducted over a period of 2 years (1 October 2002 through 30 September 2004). Patients were recruited from the pediatric department at the Royal Marsden Hospital (Sutton, United Kingdom).
Eligible patients were previously vaccinated recipients of autologous or allogeneics who were aged 1-18 years. All patients had undergone HSCT for underlying malignancies. Informed consent was obtained from the patient or his/her parent. Patients who refused the administration of у1 specific vaccine were still included in the study. Children were excluded from the study if there was a contraindication to receipt of a vaccine.
Clinical data on each patient were obtained from the patient, parents, and patient records. Past vaccination details were obtained from parents or the patient's general practitioner. Vaccines and schedule. Revaccination commenced у12 months after autologous and HLA-identical sibling HSCT and у18 months after any other allogeneic HSCT, providing that there was no evidence of active chronic GvHD and that the patient had not been receiving any immunosuppressive treatment for 6 months (12 months for MMR). Vaccines were administered as detailed in table 1.
A randomized component for pneumococcal vaccines was incorporated into the study. This compared 2 schedules: (1) administration of PCV7 at 15 and 16 months after transplantation and administration of PnPS-23 at 24 months after transplantation, and (2) administration of PnPS-23 at 15 and 24 months after transplantation. The scheduled administrations were started 6 months later for "other" allogeneic HSCT. Patients were randomized to 1 of the 2 schedules by The Royal Marsden Hospital clinical trials department. Patients who did not participate in the randomization were vaccinated with PCV7.
The vaccines administered were diphtheria-tetanus-acellular pertussis (DTaP; Infanrix; GlaxoSmithKline), inactivated poliovirus vaccine (IPV; Imovax; AventisPasteur), Hib conjugate (Hiberix; GlaxoSmithKline), MCC (Meningitec; Wyeth), MMR (MMR II; AventisPasteur), PCV7 (Prevnar; Wyeth), and Pn-PS23 (Pneumovax; AventisPasteur).
Serologic testing. Blood samples were obtained for serological testing at the same time that specimens were obtained for routine blood tests, when possible. Blood samples were collected on the day that revaccinations were commenced and then 2-4 weeks after vaccination, as indicated in table 1. Five to 10 mL of blood was collected. Blood was centrifuged, and serum was separated and frozen in aliquots at Ϫ20ЊC on the same day at the Royal Marsden Hospital, until the samples were tested in batches. Serum samples were transported frozen to the various laboratories.
Antibody assays. Serum antibody concentrations or titers were measured for the following antigens: Hib; tetanus; poliovirus serotypes 1, 2, and 3; measles; meningococcus C; and Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 9V, 18C, 19F, and 23F.
Tetanus and Hib assays were performed at the Protein Reference Unit at St. George's Hospital (London, UK). ELISA methods were used to measure levels of IgG antibody to tetanus toxoid (using an in-house method validated by the Protein Reference Unit) and polyribosylribitol phosphate (PRP; Bindazyme; the Binding Site). A neutralization assay was used to detect neutralizing antibodies against poliovirus serotypes 1, 2, and 3 and was performed at the Health Protection Agency (Colindale, London) [20] . The plaque reduction neutralization assay was used to measure neutralizing measles antibodies. Ti- ters were reported as the reciprocal of the highest serum dilution required to reduce the plaques of the challenge virus by 50%. End point titers were converted into concentrations by direct comparison with the World Health Organization standard for antimeasles serum [21] ; this assay was performed at the Health Protection Agency (Colindale). The level of serum bactericidal antibody against meningococcus C was determined using the serum bactericidal assay, with baby rabbit serum used as an exogenous complement source [22] . Serum bactericidal antibody titers are expressed as the reciprocal of the final serum dilution yielding 50% killing of bacteria; this assay was performed at the Meningococcal Reference Unit (Manchester, UK). Antibody concentrations against 9 pneumococcal serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F) were measured using a multiplex assay [23] . All serotypes are represented in the Pn-PS23 vaccine, and serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F are represented in the PCV7 vaccine. This assay was performed at the Meningococcal Reference Unit (Manchester). Statistical analysis. Antibody concentrations or titers that were less than the limit of the assay's sensitivity were assigned values equal to one-half of the lower detection limit for statistical analysis. All antibody concentrations and titers were logtransformed to calculate the geometric mean concentration (GMC) and geometric mean titer (GMT) with 95% CIs. Data did not conform to a normal distribution; thus, comparisons of GMC and GMT before and after vaccination (paired samples) were performed using Wilcoxon's signed rank test, comparisons between 2 groups (unpaired samples) were performed using the Mann-Whitney U test, and 3-way comparisons were performed using the Kruskal-Wallis test. Comparisons of proportions were analyzed using Fisher's exact test in all cases. Correlation between 2 continuous variables was analyzed with Spearman's correlation coefficient.
Data are also reported in terms of proportions of subjects who had seroconversion (defined as a у4-fold increase in antibody concentration or titer) and of protective concentrations or titers. For Hib, anti-PRP antibody concentrations у0.15 and у1.0 mg/mL are traditionally thought to correlate with shortterm and long-term protection, respectively [24] . For tetanus, antitetanus antibody concentrations of 0.01 and 0.1 IU/mL are correlated with short-term and long-term protection, respectively [25] . Any detectable titer of neutralizing antibody against poliovirus is considered to be protective against disease; for this study, neutralizing antibody titers у1:8 were considered to correlate with protection [25] . For measles, a concentration у120 mIU/mL is believed to correlate with protection against measles (Cohen B, Audet S, Andrews N, Beeler J, on behalf of the World Health Organization Working Group on Measles Plaque Reduction Neutralization Test; personal communication). For meningococcus C, a serum bactericidal antibody titer у1:8 before vaccination and a serum bactericidal antibody titer у1:128 after vaccination are believed to correlate with protection [26, 27] . Serum bactericidal antibody titers in the range of 1:8-1:64 after vaccination are considered to be protective if immunization results in a у4-fold increase in serum bactericidal antibody titer [26] . For pneumococcal disease, a serotype-specific antibody concentration у0.35 mg/mL is considered to correlate with protection [28] .
Analysis findings were considered to be statistically significant at a 2-tailed P value of у.05. Data were analyzed using SPSS statistical program, version 12.0 for Windows (SPSS). The ethics committee of the Royal Marsden Hospital approved the study.
RESULTS
Demographic characteristics of the patients are presented in table 2. Thirty-eight HSCT recipients were recruited. The number of serologic test results obtained varied by vaccine antigen and time point (tables 3-9). Reasons for the availability of fewer samples at the later time points include the following: patients declined to provide further samples, patients did not attend a visit for blood sample collection, and the time point was not reached during the study period. The difference in numbers for vaccine antigens was the result of insufficient serum sample sizes to allow all assays to be performed.
Before transplantation, all patients had received Hib conjugate, IPV, tetanus toxoid, and MMR vaccines. Nineteen percent of patients had received MCC vaccine, and none had received the pneumococcal vaccines.
For each vaccine antigen studied, there was a significant increase in antibody level after vaccination. For Hib conjugate, tetanus toxoid, IPV, and MCC vaccines, antibody level was evaluated after administration of 3 doses and then 9 months later; for the MMR vaccine, it was evaluated after administration of the first and second doses; and for pneumococcal vaccines, it was evaluated after administration of 2 doses for PCV7 followed by 1 dose of Pn-PS23 or of 1 dose of Pn-PS23 followed by an additional dose of Pn-PS23.
There was no correlation found between pre-or postvaccination antibody levels for any vaccine antigen and the following characteristics or events: time lapse between HSCT and vaccination; time lapse between vaccination and serologic testing; the patient's age at transplantation or at vaccination; the patient's vaccination history, underlying diagnosis (for allogeneic graft recipients, this was divided into lymphoid and nonlymphoid leukemia), pretransplantation conditioning regimen, and type of graft (i.e., autologous versus allogeneic); and, for allogeneic graft recipients, whether the graft came from a related or unrelated donor, whether the graft was T cell depleted, and whether acute or chronic GvHD was present. Finally, the type of graft and presence of chronic GvHD did not influence the proportion of patients with protective nonprotective antibody levels.
Hib vaccine. Before vaccination, 63% of patients had protective anti-PRP antibody concentrations, with 19% having a level у1.0 mg/mL. There was a significant increase in antibody concentration after vaccination (table 3). All patients achieved an anti-PRP antibody concentration у1.0 mg/mL, and 86% had a у4-fold increase in concentration. Fourteen percent of patients who had protective concentrations (у1.0 mg/mL) before vaccination did not have an additional increase in the concentration after vaccination.
Tetanus vaccine. Before vaccination, 95% of patients had antibody concentrations 10.01 IU/mL, with 31% having a concentration у0.1 IU/mL. There was a significant increase in the antibody concentration after vaccination (table 4). All patients achieved concentrations у0.1 IU/mL, with 94% achieving a у4-fold increase in concentration.
Polio vaccine. Before vaccination, 29% of patients had protective neutralizing antibody titers to all 3 serotypes, as follows: serotype 1, 66%; serotype 2, 59%; and serotype 3, 34%. The GMT for serotype 3 antibody was significantly lower (P p ) than it was for serotypes 1 and 2. There was a significant .04 increase in antibody titers after vaccination (table 5) . Ninetytwo percent of patients achieved protective titers to all 3 serotypes, as follows: serotype 1, 100%; and serotypes 2 and 3, 96%. Because of vaccination, more patients achieved a у4-fold increase in antibody titer to serotype 3 than to other serotypes. After vaccination, the GMT for serotype 2 antibody was significantly lower ( ) than it was for serotypes 1 and 3 P p .01 (table 5) .
Measles vaccine. Before vaccination, 60% of patients had protective neutralizing antibody concentrations. There was a significant increase in the concentration after administration of each dose of the MMR vaccine (table 6): 91% and 100% of patients achieved protective titers after receipt of the first and second doses, respectively. The median change in antibody concentration after receipt of the first dose was 3.6-fold (range, 0.5-fold-1963-fold), and 48% of patients achieved a у4-fold increase. For 1 patient, the antibody concentration remained the same after receipt of the first MMR dose but increased to protective levels after receipt of the second dose, and for 2 patients, vaccination resulted in a decrease in the antibody concentration, although the concentration remained 1120 mIU/mL. Administration of the second dose of the MMR vaccine resulted in a median increase in the antibody concentration MCC vaccine. Before vaccination, 11% of patients had protective serum bactericidal antibody titers. There was a significant increase in titer after vaccination (table 7). All patients experienced seroconversion and achieved protective titers.
Pneumococcal vaccine. Twenty patients (19 recipients of allogeneic transplants and 1 recipient of an autologous transplant) were vaccinated with pneumococcal vaccines. Fifteen patients agreed to randomization; 8 were allocated to the conjugate vaccine schedule, and 7 were allocated to the polysaccharide vaccine schedule. Serologic test results were available for 19 patients after they received the first dose of the pneumococcal vaccine (with 13 patients having received 2 doses of PCV7 and 6 patients having received 1 dose of Pn-PS23) and for only 6 patients after they received the later dose of Pn-PS23 (5 patients had initially received 2 doses of PCV7). Thus, comparison between completed schedules is not possible.
Prevaccination antibody concentrations were generally low; the GMC of antibody ranged from 0.05 mg/mL for serotype 18C to 0.16 mg/mL for serotype 19F (table 8) . Forty-eight percent of patients had protective antibody against at least 1 serotype, and none had protection against all PCV7-associated serotypes.
Vaccination resulted in a significant increase in serotypespecific antibody concentrations. Receipt of 2 doses of PCV7 induced a significant increase ( ) against all 7 PCV7-P p .002 associated serotypes, with 85% of patients achieving protective concentrations (table 9) . In contrast, receipt of 1 dose of Pn-PS23 induced a significant increase ( ) to serotypes 1, 5, P р .05 9V, and 18C, with only 17% of patients achieving protective concentrations. The GMC on antibody substantially increased for all serotypes after receipt of the booster dose of Pn-PS23 (table 8) , with highest responses noted for PCV7-associated serotypes and lowest responses noted for serotypes 1 and 5.
Nine months after vaccination, serum samples were available for determination of Hib, tetanus, polio, and meningococcus C antibody concentrations. There was a significant decrease in antibody concentrations (tables 3-5 and 7), although all remained in the protective range.
DISCUSSION
Considerations in selecting an optimal vaccination schedule for HSCT recipients include the period when protection is most needed, potential complications of vaccination, and the effectiveness of vaccination. Studies indicate that both time lapse after transplantation and the number of vaccine doses received Table 6 . Geometric mean concentration (GMC) of serum measles-neutralizing antibody in hematopoietic stem cell transplant (HSCT) recipients before and after receipt of 1 and 2 doses of measles, mumps, and rubella (MMR) vaccine. may determine responses [11, 12, 15, 16] . Chronic GvHD can also have an adverse influence on immune responses [3] .
At a median time of 19 months after HSCT, study patients had maintained a good level of immunity to tetanus, but only 63% remained immune to Hib, 60% remained immune to measles, 29% remained immune to all 3 poliovirus serotypes, 11% remained immune to meningococcus C, and none remained immune to the PCV7-associated serotypes. This provides an explanation for their increased susceptibility to infection and reinforces the need for a revaccination program. Our patients demonstrated a good level of persistence of antibody to tetanus after HSCT and a good immune response to revaccination with 3 doses of tetanus toxoid vaccine. It is conceivable that administration of !3 doses may suffice for revaccination of HSCT recipients, but this requires additional study. For example, Ljungman et al. [12] demonstrated that 90% of recipients can respond to 2 doses.
The prevailing GMC of anti-PRP for our HSCT recipients was low (0.34 mg/mL) but was similar to that reported in healthy British children of a similar age [29] . Vaccination resulted in all recipients achieving concentrations у1.0 mg/mL, with a GMC equivalent to that of healthy infants after receipt of 3 doses [30] . This suggests that the response of HSCT recipients to Hib vaccine may be a primary rather than a secondary immune response. This is, to our knowledge, the first study to measure im- Table 8 . Geometric mean concentration (GMC) of serum serotype-specific pneumococcal antibody in hematopoietic stem cell transplant recipients. munity against meningococcus C disease and the immune response to MCC in pediatric HSCT recipients. MCC vaccines were only licensed in the United Kingdom in 1999, explaining the low coverage in this group before HSCT. Administration of a single dose of MCC to adult asplenic individuals results in a serum bactericidal antibody GMT of 1:158 [31] , and healthy infants after 3 doses of MCC achieve serum bactericidal antibody GMT of 1:1057 [32] to 1:3082 [33] . Our patients have thus achieved very satisfactory serum bactericidal antibody titers.
As a consequence of the potential risk of virus dissemination, as well as the developmental maturation of the immune response to measles [34] , vaccination with measles vaccine is recommended at least 1 year after HSCT. A recent study has demonstrated that measles vaccination is both safe and immunogenic if given earlier [35] . Our study is, to our knowledge, the first to evaluate the immune response to 2 doses of MMR vaccine. Ninety percent of patients who experienced seroconversion after receipt of the first dose had prevaccination neutralizing antibody concentrations !120 mIU/mL; greater increases in antibody levels have been shown to occur in persons with lower prevaccination antibody concentrations [35] . Some of our recipients exhibited primary vaccine failure, which has been observed by other authors [9] , demonstrating the need for a second dose of MMR vaccine.
Pneumococcal polysaccharide vaccines are often poorly immunogenic in HSCT recipients [14, 16] , but nonetheless, they have been recommended as part of the revaccination protocol [36] . The new pneumococcal conjugate vaccines hold great promise, but there are few data on their immunogenicity in this population. Such vaccines have been shown to be immunogenic in pediatric solid-organ transplant recipients [37] . Before vaccination, the majority of patients had nonprotective concentrations to the 9 serotypes examined, suggesting a basis for their susceptibility to pneumococcal disease. All study patients achieved significant increases of serotype-specific antibody concentrations after receipt of the first pneumococcal vaccination. There was marked serotype variation in response, as observed in other studies [37, 38] . Recipients of 2 doses of PCV7 achieved higher antibody GMC to PCV7-associated serotypes than did recipients of 1 dose of Pn-PS23; 92%-100% of recipients of 2 doses of PCV7 achieved protective concentrations to the PCV7-associated serotypes. After administration of the booster dose of pneumococcal polysaccharide vaccine in previous conjugate recipients, very high concentrations against all PCV7 serotypes were achieved. Although these responses are promising, they were derived from a relatively small number of subjects, and studies should be repeated with a larger number of subjects. Given the elevated risk of pneumococcal disease in this population [39] and the good immune responses to other conjugates, vaccination with PCV7 could perhaps be considered earlier in the schedule.
In summary, the majority of HSCT recipients achieve protective responses to vaccinations when vaccines are given in accordance with this relatively simple revaccination schedule. The recent European Group for Blood and Marrow Transplant guidelines [19] recommend that some vaccinations may be given earlier than in the British schedule. Our data suggest that this is worthy of formal study and also provide a platform from which other schedules may be tested. This current schedule should also be applicable in other countries where similar HSCT protocols are followed.
